BCL2 and cancer: Accordingly, increased levels of BCL-2 expression have been correlated with resistance to several anti-cancer drugs, including 5-fluorouracil, adriamycin and mitomycin, in gastric cancer [193], cisplatin in ovarian cancer [194] and doxorubicin in osteosarcoma and chondrosarcoma [195, 196].